Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes.
about
Aromatase Inhibitors for the adjuvant treatment of breast cancer in postmenopausal womenThresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancerIntroduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.The Impact of CYP2D6 Genotyping on Tamoxifen TreatmentTailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System.The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancerLocoregional Recurrence and Survival Rates after Breast-Conserving Surgery and Hormonal Therapy in 70-Year-Old or Older Patients with Stage I or IIA Breast CarcinomaTamoxifen: the drug that came in from the cold.Breast cancer recurrence in older women five to ten years after diagnosis.Update on the use of aromatase inhibitors in early-stage breast cancer.Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.Real-world impact of non-breast cancer-specific death on overall survival in resectable breast cancer.Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia.Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole.No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen
P2860
Q24194371-FAAD95BB-6359-447F-9E3E-BDD14539BA99Q24657145-1EA3C757-258A-4AF5-AF65-7D69D58BA3ECQ27008869-3D5065E9-6C1A-4E39-BE70-24325D54EBD5Q33555532-C792C1CB-B2B3-4A13-A6BA-76B87F1363ACQ33664433-C2D867B4-1C6D-422C-98D3-70674953867FQ33781027-AF0A17D4-E114-4C96-85A5-4D8274F7768CQ34173419-AB301BA4-4954-4D04-9F99-B286D57FD208Q34278775-07D8C32C-0948-4B85-B57B-1A69BD18CD15Q35012609-1D195517-C594-4CE3-9263-55321684E385Q35671180-817F3137-6DC8-4443-9C08-0FCA7BF177DEQ36169971-0CDB5F1F-EC64-4AB7-865E-54FBA9716715Q36932980-9DE25BCD-3F6D-4ADF-91CB-FEF837FE3EBAQ37345339-59322345-F310-42DE-A1AE-B2AC3404FD6BQ37442431-EAF2C840-19C1-428D-BC6E-CAE531CBD0FFQ37467243-70A8498A-87B2-470C-913F-9FEC096B8597Q37483932-3D75656A-9101-4C3F-9292-4305F3E69729Q38749680-1D11CFB4-E596-48B9-B524-5D30D9791FB8Q43571676-3E98A1D3-44B8-49E8-AB8B-783996627CC6Q47966705-0C88E844-71F0-499A-80D0-9A65A8636B92Q55422094-6C834644-C310-4BD7-B42E-8B0E1CB13687Q58215078-6136AA13-4AB9-43D9-873C-C435982796FB
P2860
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@ast
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@en
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@nl
type
label
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@ast
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@en
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@nl
prefLabel
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@ast
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@en
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@nl
P356
P1476
Up-front use of aromatase inhi ...... r: the emperor has no clothes.
@en
P2093
Bostjan Seruga
Ian F Tannock
P304
P356
10.1200/JCO.2008.19.5594
P407
P577
2009-01-12T00:00:00Z